[Asthenia in adolescents with attention deficit disorder and their treatment]. / Asteniia u podrostkov s sindromom defitsita vnimaniia i ikh lechenie nooklerinom.

AIM: To study asthenia in adolescents with attention deficit hyperactivity disorder (ADHD) and assess the efficacy of nooclerin. MATERIAL AND METHODS: We examined 60 patients, aged from 12 to 15 years, with ADHD. A comparative analysis of ADHD demonstrated the predominance of an inattentive type (ADHD-I) and a combined type (ADHD-C). RESULTS AND CONCLUSION: Symptoms of asthenia were found in 56% of adolescents with ADHD-C and in 96.7% with ADHD-I. The high efficacy and safety of nooclerin in the treatment of ADHD was demonstrated. The improvement of mental state was achieved in 76.7% of patients with ADHD-I and in 53.3% patients with ADHD-C.

[Comorbidity of tics and stuttering].

OBJECTIVE: To determine the clinical presentations of stuttering in children with tics treated with noofen. MATERIAL AND METHODS: Authors examined 181 children with tics, aged 7-13. Stuttering was identified in 23.2% of cases. Thirty children with tics and comorbid stuttering received noofen. RESULTS AND СONCLUSION: The prevalence of stuttering in children with tics was significantly higher than in the population. Stuttering was significantly more frequent in children with transient tics than chronic tics. Neurotic stuttering was recorded more frequently. The high efficacy of noofen was shown; the decrease in ticks was obtained in 80% of cases, the reduction of stuttering in 66.7% of cases. The data of clinical, psychological and neurophysiological studies, confirming the improvement of patients after treatment, are presented.

[Cognitive and emotional impairments in patients with protracted anxiety-phobic disorders].

AIM: To study cognitive and emotional impairments in patients with anxiety-phobic disorders (APDs), to comparatively analyze the clinical manifestations of acute (less than one-year) and protracted (1-to-5-year) forms of this disease, and to evaluate the efficacy of noofen used to treat this pathology. SUBJECTS AND METHODS: Sixty-two patients aged 18 to 50 years with APDs were examined. The investigators collected clinical history data, performed neurological examination, and assessed autonomic disorders in accordance with the questionnaire to reveal their signs, anxiety using the Hamilton anxiety rating scale, memory impairment employing the methods developed by A.R. Luria, attention disorders applying the test of variables of attention, and diagnosed emotional intelligence using the Mayer-Salovey-Caruso emotional intelligence test. Noofen 1000 mg/day was used to treat the patients. RESULTS: Protracted APDs were shown to be characterized by the higher degree of psychosomatic symptoms and by more pronounced impairments in attention, memory, and emotional intelligence. The data of posttreatment clinical and psychological studiesare indicative of improvements in 73.3% of cases. CONCLUSION: The findings may lead to the conclusion that noofen is highly effective in the treatment of patients with protracted APDs.

[Asthenic disorders in children and their differentiated treatment].

OBJECTIVE: To study clinical/psychological characteristics of neurasthenia and residual asthenia and to assess the efficacy of noofen and adaptol in the treatment of these disorders. MATERIAL AND METHODS: Authors examined 30 adolescents with neurasthenia and 30 with residual asthenia. The Multidimensional Fatigue Inventory (MFI-20), A.M. Vein questionnaire, Spilberger-Khanin questionnaire, The Test of Variables of Attention (TOVA) were used. Patients were divided into two equal groups (n=30), each included 15 patients with residual asthenia and neurasthenia. Patients of the first group received adaptol in dosage 1000 mg daily and patients of the second group received noofen in dosage 500 mg daily. The duration of the study was 30 days. RESULTS AND CONCLUSION: The significantly higher levels of fatigue, inattention and exhaustibility were identified in patients with residual asthenia. Adolescents with neurasthenia were characterized by higher anxiety. The higher efficacy of adaptol in treatment of neurasthenia (80% in adolescents with neurasthenia and 60% of patients with residual asthenia) was shown. Noofen was more effective in treatment of residual asthenia (66.7% of adolescents with neurasthenia and 86.7% with residual asthenia.

[Attention deficit syndrome in adults: clinical, psychophysiological features and treatment].

The authors present the results of examination of 34 patients, aged from 18 to 30 years, with attention deficit hyperactivity disorder (ADHD) (ICD-10 item F90.0). The study has shown that inattentive type of ADHD is noted in 50%, combined type in 38.3% and hyperactivity/impulsivity type in 11.7% of patients. Adult patients with ADHD also have a high level of anxiety and asthenic disorders. This study evaluated the efficacy and safety of adaptol in dosage 1500 mg daily during 8 weeks in the treatment of this group of patients. The high efficacy (improvement in 64,7% of cases) and safety of adaptol confirmed by the data of clinical, psychological and neurophysiological studies.

[Asthenic syndrome in patients with burnout syndrome].

The authors present the results of a survey of 103 patients aged 25 to 45 years with burnout syndrom. The results showed that most patients with the syndrome of burnout have clinical manifestations of asthenia, varying degrees of severity. According to psychological and psychophysiological examination in this group of patients were found attention and memory dysfunction. This study evaluated the efficacy of memoplant in the treatment of this pathology. The high efficiency of memoplant (improvement in 69.7% of cases) was detected, confirmed by the data of the clinical, psychological and neuropsychological research.

[Chronic tic disorders in children and adolescents and their treatment with adaptol].

We examined 162 patients, aged from 10 to 15 years, with tic hyperkineses. Transient and chronic tic disorders were observed in 82 and 80 patients, respectively. The relationship of clinical features, frequency, psychological and encephalographic characteristics of the patients with age-at-onset was studied. The effect of adaptol on the course of chronic tic disorders was evaluated. In addition to our results reported previously for transient tic disorders, we demonstrated the efficacy of adaptol administered in dose 1000 mg per day during 60 days in patients with chronic tic disorders.

[Efficacy of cortexin in the treatment of memory disorders in children].

Children, aged from 7 to 12 years, with memory disorders were treated with cortexin (30 patients) and encephabol (30 patients). The comparative evaluation of efficacy and safety of these drugs was carried out. The higher cortexin efficacy (the improvement in 86.7% of cases) in comparison with encephabol (the improvement in 63.3% of cases) confirmed by the data of neuropsychological and neurophysiological research is established.

[Clinical and neurophysiological study of the efficacy of adaptol in the treatment of emotional burn-out].

The study aimed at therapeutic effect of adaptol on burn-out syndrome. Authors examined 32 patients aged from 25 to 45 years. Adaptol was prescribed in day dose 1500 mg during 60 days. Clinical, psychological and electroencephalographic study (EEG) was conducted before and after the treatment course. The data of adaptol positive influence on the basic clinical symptoms (reduction of asthenic and anxiety scores) is obtained. The analysis of EEG results allows to draw conclusions on normalisation of brain functional activity after therapy.

[Asthenic disorders in children].

The present study comprised two parts. In the first part, authors attempted to work out the systematics of asthenic disorders based on our own observations of 189 children aged 7-14 years. The following clinical variants of asthenic states in children were singled out: cerebrogenic asthenia (14.3%), somatogenic (13.8%), residual (16.4%), dysontogenetic (20.1%) and neurasthenia (35.4%). In the second part, we summarized the results of treatment of neurasthenia with adaptol (32 patients) compared to pantoham (30 patients). The efficacy of adaptol was higher: the improvement was seen in 71.9% of cases compared to pantoham (56.7%). The good tolerability of adaptol which clinical efficacy is confirmed by neurophysiological and psychological studies is discussed.

[Headaches of tension: clinical-psychological variants and perspectives of therapy].

We examined 72 patients with headache of tension (HAT), 56 women and 16 men, aged from 18 to 45 years (mean age 32,7+/-8,5 years). Frequent HAT was diagnosed in 48 cases and chronic HAT - in 24 cases. Clinical-psychological and electroencephalographic study was conducted before and after the treatment with adaptol. The results were compared to those of the control group. This group included 30 patients treated with alprazolam. Two clinical variants of the disease were singled out: asthenic (25 patients) and anxiety (47 patients). The correctness of the identification was confirmed by electroencephalographic data. The higher efficacy of adaptol was noted in frequent HAT. During the treatment, there was the reduction of severity of cephalgia syndrome and of anxiety and asthenic scores as well, while depression scores did not change. Adaptol was more effective compared to alprazolam.

[Adaptol in the treatment of anxiety disorders in children with school maladaptation].

We examined 336 children, aged 7-14 years, with signs of school maladaptation (SM). Anxiety disorders were found in 167 (49.7%), including generalized anxiety disorder - 87 children (25.9%), phobic disorder - 40 children (11.3%), anxiety disorder - 14 (4.2%), social anxiety disorder - 26 (7.7%). These indices differed significantly from those in the comparison group of children without SM. The children with generalized anxiety disorder were treated with adaptol (1000 mg/d during 30 days). The clinical and psychological examination revealed the high efficacy of this drug. Adaptol was well-tolerated, with no side-effects observed.

[Adaptol in the treatment of ADHD].

Effectiveness of adaptol, a non-benzodiazepine tranquilizer, in the treatment of ADHD has been studied. The use of adaptol in dosage 500 mg 2 times daily during one month resulted in the decrease of hyperactivity and impulsivity and did not exert any influence on attention and reaction time. The authors emphasize the importance of this fact due to its relation to side-effects which are often seen in the treatment with benzodiazepine tranquilizers. It has been concluded that adaptol may be used in the treatment of ADHD as a monotherapy in cases with predominance of hyperactivity/impulsivity and as a complex therapy in other diseases especially in the combination of ADHD and anxiety disorders.